GENE ONLINE|News &
Opinion
Blog

Remdesivir
Remdesivir Cleared for Treating Non-Hospitalized COVID-19 Patients
2022-01-24
As India Suffers Crisis, Merck Signs License Pact with 5 Indian Firms to Manufacture COVID-19 Drugs
2021-04-29
A 11-Year-Old, Survivor-Derived Antibody Becomes Second Ebola Therapy to Bag FDA Approval
2020-12-23
First to the Finish Line! Remdesivir Becomes the First and Only FDA Approved Drug to Treat COVID-19
2020-10-23
Innovative Diagnostics, AI, Blockchain and Telemedicine Boosts COVID-19 Fight
2020-07-26Partner
Dexamethasone Renews Hopes for a Life Saving COVID-19 Treatment
2020-06-20
Remdesivir Registers Middling Benefit in Patients with Moderate COVID-19
2020-06-01
Potential Repurposed Drugs Currently in Evaluation for COVID-19
2020-05-01
COVID-19: Gilead’s Promising Remdesivir Data Jumps US Stocks, Hastens FDA’s Emergency Authorization Plans
2020-04-29
Coronavirus Drugs: Studies Show Remdesivir’s Activity against Viral Enzyme
2020-04-15
Remdesivir’s Early Trial Data Necessitates Guarded Optimism
2020-04-12
Gilead Requests FDA to Rescind Remdesivir’s Orphan Drug Designation
2020-03-25
Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment
2020-03-24
Taiwan’s Action Strategies Provide Great Model to Fight Coronavirus
2020-03-16
COVID-19 Victims on Remdesivir Treatment Hopeful after First US Patient Recovers
2020-03-12
1 2
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!